Related Experiment Video

Updated: Apr 17, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma

Ilya Tsimafeyeu1, Gennady Bratslavsky

  • 1Kidney Cancer Research Bureau, Moscow, Russia.

Oncology
|February 14, 2015
PubMed

Insights

Fibroblast growth factor receptor 1 (FGFR1) plays a key role in renal cell carcinoma. Targeting the FGF/FGFR pathway offers a promising therapeutic strategy for patients with FGFR1-driven tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Fibroblast growth factor (FGF) signaling is frequently dysregulated in renal cell carcinoma (RCC).
  • Tumor cells can become dependent on activated FGF/FGFR signaling for growth and survival.
  • This pathway represents a potential therapeutic target in specific RCC subtypes.

Purpose of the Study:

  • To review the role of Fibroblast Growth Factor Receptor 1 (FGFR1) in renal cell carcinoma pathogenesis.
  • To discuss the therapeutic potential of targeting the FGF/FGFR axis in RCC.
  • To examine methodological challenges in developing drugs targeting this pathway.

Main Methods:

  • Literature review of existing data on FGFR1 in RCC.
  • Analysis of the FGF/FGFR signaling pathway in cancer biology.
  • Discussion of drug development strategies and challenges.

Main Results:

  • FGFR1 is implicated in the development and progression of renal cell carcinoma.
  • Dysregulation of the FGF/FGFR pathway is a common feature in certain RCC tumors.
  • Targeting FGFR1 presents a viable therapeutic avenue for selected RCC patients.

Conclusions:

  • FGFR1 is a significant factor in RCC pathogenesis.
  • Targeting the FGF/FGFR axis offers a promising therapeutic strategy for RCC.
  • Further research into drug development methodologies is crucial for clinical application.

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

5.2K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K